AND019 not checked

Kind Pharmaceuticals LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“AND019 administrated as oral capsule once per day for 28 days for each cycle”In the company’s words, NCT05187832 on ClinicalTrials.gov
Tested for
Advanced or Metastatic Breast Cancer
Main trialPhase 1
“This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.”In the company’s words, NCT05187832 on ClinicalTrials.gov

Other drugs for Advanced or Metastatic Breast Cancer

All 397 drugs for Advanced or Metastatic Breast Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Nov 2026 A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AND019

Following is part of Solo: you see every change to AND019 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in